Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

A backlash against a White House video promoting deportation and Casalonga opening a new office in Düsseldorf were also among the top talking points ...

Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top pharmaceutical stocks. While the firm’s weight loss drugs are one reason the CNBC TV host likes it, he’s also bullish on Eli Lilly and ...

“We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.” Facility opens CVS Health has opened its new Workforce ...

Eli Lilly's stock showed surprising stability, with minimal movement despite significant pipeline developments. The ...

INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a ...